Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer

Syndax Pharmaceuticals reported positive results from the AUGMENT-101 trial of revumenib in mutant NPM1 AML patients, achieving a 23% CR/CRh rate. The drug showed a 4.